Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Oxurion NV

  • Patrik De Haes, OXURION NV

Oxurion NV is a leading ophthalmology biopharmaceutical company developing treatments to preserve vision for patients with diseases affecting the back of the eye. It has engineered a diverse portfolio of best-in-class disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. Oxurion’s clinical pipeline consists of THR-317, an anti- PlGF antibody in phase 2 for the treatment of DME, and in a phase 2 for MacTel 1; THR-149, a plasma kallikrein inhibitor for the treatment of DME; and THR-687, a pan-RGD integrin antagonist for the treatment of DR, DME, and wet AMD.

  • Date:Tuesday, February 12
  • Time:11:15 AM - 11:30 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23360
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Overall awareness, investor education and partnering
  • Company Website:www.oxurion.com
  • Company HQ City:LEUVEN
  • Company HQ Country:Belgium
  • Ticker:OXUR
  • Exchange:EURONEXT
  • CEO/Top Company Official:Patrik De Haes, MD
  • Year Founded:2006
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development:THR-317, THR-149, THR-687
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:THR-317 (phase II x 2), THR-149 (phase I), THR-687 (phase I)
Speakers
Patrik De Haes
OXURION NV
Back